HIV infection and bone mineral density in middle-aged women

Clinical Infectious Diseases

Volumn 42, Issue 7, 2006, Pages 1014-1020

  Arnsten, Julia H ^a,b   Freeman, Ruth ^a   Howard, Andrea A ^a   Floris Moore, Michelle ^a   Santoro, Nanette ^a   Schoenbaum, Elite E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ESTROGEN; METHADONE; PREDNISONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ARTICLE; BEHAVIOR; BODY WEIGHT; BONE DENSITY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG ABUSE; DRUG USE; FEMALE; FEMUR NECK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; BONE DENSITY; BONE REMODELING; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; METHADONE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS;

EID: 33645062397     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501015     Document Type: Article

References (36)

1. Slemenda C, Hui SL, Longcope C, Johnson CC. Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 1987; 80:1261-9.
2. Manolagas SC, Jilka RL. Mechanisms of disease: Bone marrow, cytokines, and bone remodeling-emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305-11.
3. Haug CJ, Aukrust P, Haug E, Morkrik L, Muller F, Froland SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998; 83:3832-8.
4. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145-50.
5. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7:178-208.
6. Rizzoli R, Bonjour JP. Determinants of peak bone mass and mechanisms of bone loss. Osteoporos Int 1999; 9(Suppl 2):S17-S23.
7. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997; 315:841-6.
8. Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 1983; 117:651-8.
9. Michnovicz JJ, Naganuma H, Hershcopf RJ, Bradlow HL, Fishman J. Increased urinary catechol estrogen excretion in female smokers. Steroids 1988; 52:69-83.
10. Schweiger U, Deuschle M, Korner A, et al. Low lumbar bone mineral density in patients with major depression. Am J Psychiatry 1994; 151:1691-3.
11. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Ann Epidemiol 1994; 4:214-20.
12. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Engl J Med 1996; 335:1176-81.
13. Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37(2 Suppl):S132-6.
14. Grinspoon S, Corcoran C, Miller K, et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 1997; 82:1332-7.
15. Cofrancesco J, Whalen JJ, Dobs AS. Testosterone replacement treatment options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:254-65.
16. Loiseau-Peres S, Delaunay C, Poupon S, et al. Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine 2002; 69:482-5.
17. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89:1200-6.
18. Vescini F, Borderi M, Buffa A, et al. Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr 2003; 33:405-7.
19. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004; 19:402-9.
20. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS 2001; 15:1731-3.
21. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-23.
22. Landonio S, Quirino T, Bonfanti P, et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother 2004; 58:505-8.
23. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15:703-9.
24. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-83.
25. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-7.
26. Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001; 15:807-8.
27. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-80.
28. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001; 15:975-82.
29. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
30. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-90.
31. Miller SA, Santoro N, Lo Y, et al. Menopause symptoms in HIV-infected and drug-using women. Menopause 2005; 12:348-56.
32. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005; 40:1492-9.
33. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older US women from NHANES III. J Bone Miner Res 1995; 10:796-802.
34. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003; 46:221-7.
35. Meier DE, Luckey MM, Wallenstein S, Lapinski RH, Catherwood B. Racial differences in pre- and postmenopausal bone homeostasis: association with bone density. J Bone Miner Res 1992; 7:1181-9.
36. Luckey MM, Wallenstein S, Lapinski R, Meier DE. A prospective study of bone loss in African-American and white women-a clinical research center study. J Clin Endocrinol Metab 1996; 81:2948-56.